Chardan Healthcare Acquisition, a special purpose acquisition company, completed the $134m acquisition of BiomX, a microbiome company developing both natural and engineered phage therapies. $134m reflects value of Equity and Net Cash of BiomX "We believe this transaction leaves BiomX with a strong balance sheet and sufficient cash for the company to reach multiple value inflection points in its leading clinical programs. We also believe we have structured a transaction that will deliver value to all stakeholders and create opportunity for new investors. We are excited to make use of inherent features of the SPAC in combination with the fundamental qualities of BiomX and supportive shareholders for the benefit of all of our partners." Jonas Grossman, CHAC's President and Chief Executive Officer.